Dynamics of hepatitis C virus infection

Ann Hepatol. 2002 Apr-Jun;1(2):56-63.

Abstract

Viremia shows only minor fluctuations in untreated patients chronically infected with hepatitis C virus. The steady state situation of balanced viral production and clearance in untreated patients can be disturbed by active antiviral treatment. After initiating interferon- alpha therapy, a typical biphasic decline of viremia can be observed and analyzed. Evaluation of mathematical models of viral dynamics during the initial phase of antiviral treatment shows high turnover rates of pre-treatment viral production and clearance of about 10(11) -10(13) virions each day and in-vivo half-lives of a few hours for free hepatitis C virions. During the first 24 to 48 hours of therapy, a dose-dependent first phase of interferon-alpha induced viral kinetics is characterized by a rapid exponential decline of serum viral load. Then viral decline enters a second phase of a relatively slow exponential decay during the following weeks of therapy which mainly reflects the death rate of infected hepatocytes. This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Drug Therapy, Combination
  • Hepacivirus / genetics
  • Hepacivirus / metabolism*
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / metabolism
  • Hepatitis C, Chronic / virology*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / pharmacokinetics
  • Interferon-alpha / therapeutic use*
  • Models, Theoretical
  • Polyethylene Glycols / pharmacokinetics
  • Polyethylene Glycols / therapeutic use*
  • RNA, Viral / blood*
  • RNA, Viral / genetics
  • Recombinant Proteins
  • Ribavirin / pharmacokinetics
  • Ribavirin / therapeutic use*
  • Viral Load
  • Viremia / drug therapy*
  • Viremia / metabolism

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a